EICHORCondition: Antibody-mediated Rejection · Sponsor: CSL Behring
This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham (UAB) - University of Alabama Hospital (UAB Hospital) | Birmingham, Alabama, United States | — |
| Mayo Clinic Hospital | Phoenix, Arizona, United States | — |
| Keck Medical Center Of USC | Los Angeles, California, United States | — |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | — |
| UCLA Kidney Transplant Research Program | Los Angeles, California, United States | — |
| University of California Davis Medical Center | Sacramento, California, United States | — |
| California Institute of Renal Research | San Diego, California, United States | — |
| North America Research Institute | San Dimas, California, United States | — |
| California Pacific Medical Center | San Francisco, California, United States | — |
| Kaiser Permanente | San Francisco, California, United States | — |
| University of California, San Francisco Medical Center | San Francisco, California, United States | — |
| University Of Colorado Hospital - Anschutz Medical Campus | Aurora, Colorado, United States | — |
+ 130 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03744910